share_log

Salarius Pharmaceuticals Issued U.S. Patent for Next-Generation Targeted Protein Degraders

Salarius Pharmaceuticals Issued U.S. Patent for Next-Generation Targeted Protein Degraders

Salarius Pharmicals 發佈了下一代靶向蛋白質降解劑的美國專利
GlobeNewswire ·  01/16 21:00

Expands IP portfolio with composition-of-matter protection into 2039 for novel molecular glues

將具有物質成分保護的新型分子膠的知識產權組合擴展到2039年

Protein degrader portfolio now includes 17 issued patents across six patent families

蛋白質降解劑產品組合現在包括六個專利家族的17項已頒發的專利

HOUSTON, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), announces that the U.S. Patent and Trademark Office (USPTO) has issued U.S. Patent No. 11,773,080, titled "Deuterium-enriched isoindolinonyl-azepanediones and related compounds and methods of treating medical disorders using same." This patent covers the composition of matter for novel molecular glue degraders and expires in mid-2039.

休斯頓,2024年1月16日(GLOBE NEWSWIRE)——Salarius Pharmicals, Inc.(納斯達克股票代碼:SLRX)宣佈,美國專利商標局(USPTO)已頒發了第11,773,080號美國專利,標題爲 “富含氘的異吲哚啉酰-氮卓烷二酮和相關化合物以及使用這些化合物治療醫學疾病的方法”。該專利涵蓋了用於新型分子膠水降解劑的物質成分,並將於2039年中期到期。

As reported on August 8, 2023, Salarius retained Canaccord Genuity, LLC to lead a comprehensive review of strategic alternatives focusing on maximizing shareholder value. While these efforts are ongoing, the company continues to support its current programs, as appropriate.

正如2023年8月8日報道的那樣,Salarius聘請了Canaccord Genuity, LLC來領導對以股東價值最大化爲重點的戰略替代方案的全面審查。在這些努力仍在進行中,該公司將繼續酌情支持其當前計劃。

Targeted protein degradation (TPD) utilizes the body's own degradation system to promote the selective elimination of disease-causing proteins. This newly issued patent expands and extends protection of Salarius' TPD pipeline, which is led by SP-3164, a molecular glue that is cleared by the U.S. Food and Drug Administration to begin a Phase 1 clinical trial.

靶向蛋白質降解(TPD)利用人體自身的降解系統來促進致病蛋白質的選擇性消除。這項新頒發的專利擴大並延長了對Salarius的TPD管道的保護,該產品線由 SP-3164 領導,這是一種分子膠水,已獲得美國食品藥品監督管理局的批准,可開始1期臨床試驗。

David Arthur, President and CEO of Salarius, said, "We are delighted to continue building our TPD portfolio using our deuterium-enabled chiral switching (DECS) platform to identify and develop new therapeutics. The granting of this patent, the 17th issued to Salarius in TPDs across six patent families, demonstrates the ability of the DECS platform to develop novel protein degraders."

Salarius總裁兼首席執行官大衛·亞瑟表示:“我們很高興繼續使用我們的支持氘的手性切換(DECS)平台建立我們的TPD產品組合,以識別和開發新的療法。該專利的授予,即17項第四 向Salarius發放的六個專利家族的TPDs證明了DECS平台開發新型蛋白質降解劑的能力。”

Salarius is currently evaluating strategic options to advance the development of the TPD portfolio with third parties.

Salarius目前正在評估戰略選擇,以推動與第三方共同開發TPD產品組合。

About Salarius Pharmaceuticals
Salarius Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing therapies for patients with cancer in need of new treatment options. Salarius' product portfolio includes seclidemstat, Salarius' lead candidate, a potential treatment for pediatric cancers, sarcomas and hematologic or blood cancers, and SP-3164, an oral small molecule protein degrader for the treatment of non-Hodgkin's lymphoma. Salarius has received financial support from the National Pediatric Cancer Foundation to advance the Ewing sarcoma program and was a recipient of a Product Development Award from the Cancer Prevention and Research Institute of Texas (CPRIT). For more information, please visit salariuspharma.com or follow Salarius on Twitter and LinkedIn.

關於薩拉里烏斯製藥
Salarius Pharmaceuticals, Inc. 是一家處於臨床階段的生物製藥公司,爲需要新治療選擇的癌症患者開發療法。Salarius的產品組合包括Salarius的主要候選藥物seclidemstat,一種潛在的兒科癌症、肉瘤和血液系統或血液癌的治療方法,以及用於治療非霍奇金淋巴瘤的口服小分子蛋白降解劑 SP-3164。Salarius獲得了美國國家兒科癌症基金會的財政支持,以推進尤因肉瘤項目,並獲得了德克薩斯州癌症預防與研究所(CPRIT)頒發的產品開發獎。欲了解更多信息,請訪問 salariuspharma.com 或在 Twitter 和 LinkedIn 上關注 Salarius。

Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this press release are forward-looking statements. These forward-looking statements may be identified by terms such as "will," "believe," "developing," "expect," "may," "progress," "potential," "could," "look forward," "encouraging," "might," "should," and similar terms or expressions or the negative thereof. Examples of such statements include, but are not limited to, statements relating to the following: Salarius' expectations regarding the exploration of strategic alternatives, opportunities to extend Salarius' resources, the future of the Company's operations and product candidates; the future of the Company's preclinical studies and clinical trials and development activities; the advantages of protein degraders including the value of SP-3164 as a cancer treatment; the value of seclidemstat as a treatment for Ewing sarcoma, Ewing-related sarcomas, and other cancers and its ability to improve the life of patients. Salarius may not actually achieve the plans, carry out the intentions or meet the expectations or objectives disclosed in these forward-looking statements. You should not place undue reliance on these forward-looking statements. These statements are subject to risks and uncertainties which could cause actual results and performance to differ materially from those discussed in the forward-looking statements. These risks and uncertainties include, but are not limited to, the following: the risk that exploration of strategic alternatives may not result in any definitive transaction or enhance stockholder value and may create a distraction or uncertainty that may adversely affect our operating results, business, or investor perceptions; expectations regarding future costs and expenses; our product candidates being in early stages of development; the uncertainty about the paths of our programs and our ability to evaluate and identify a path forward for those programs, particularly given the constraints we have as a small company with limited financial, personnel and other operating resources (including with respect to the allocation of our limited capital and the sufficiency of our capital in the near term for any path we do select); Salarius' ability to continue as a going concern; the sufficiency of Salarius' capital resources; availability of suitable third parties with which to conduct contemplated strategic transactions; whether the Company will be able to pursue a strategic transaction, or whether any transaction, if pursued, will be completed successfully and on attractive terms or at all; whether our cash resources will be sufficient to fund the Company's foreseeable and unforeseeable operating expenses and capital requirements; changes in the Company's operating plans that may impact its cash expenditures; the uncertainties inherent in research and development, future clinical data and analysis; the risks associated with reductions in workforce, including reduced morale and attrition of additional employees necessary for the strategic reprioritization; future clinical trial results and the impact of such results on Salarius; that the results of studies and clinical trials may not be predictive of future clinical trial results; the competitive landscape and other industry-related risks; and other risks described in Salarius' filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended December 31, 2022, as revised or supplemented by its Quarterly Reports on Form 10-Q and other documents filed with the SEC. The forward-looking statements contained in this press release speak only as of the date of this press release and are based on management's assumptions and estimates as of such date. Salarius disclaims any intent or obligation to update these forward-looking statements to reflect events or circumstances that exist after the date on which they were made.

前瞻性陳述
本新聞稿包含1995年《私人證券訴訟改革法》所指的 “前瞻性陳述”。除歷史事實陳述外,本新聞稿中包含的所有陳述均爲前瞻性陳述。這些前瞻性陳述可以通過諸如 “將”、“相信”、“發展”、“期望”、“可能”、“進展”、“潛力”、“可能”、“展望未來”、“鼓勵”、“可能”、“應該” 等術語以及類似的術語或表述或否定詞來識別。此類聲明的示例包括但不限於與以下內容有關的陳述:薩拉里烏斯對探索戰略替代方案的預期、擴展薩拉里烏斯資源的機會、公司業務和候選產品的未來;公司臨床前研究和臨床試驗與開發活動的未來;蛋白質降解劑的優勢,包括 SP-3164 作爲癌症治療的價值;seclidemstat作爲尤因肉瘤治療藥物的價值、Ewing 相關肉瘤和其他癌症及其改善患者生活的能力。Salarius可能無法實際實現計劃、執行意圖或實現這些前瞻性陳述中披露的預期或目標。您不應過分依賴這些前瞻性陳述。這些陳述存在風險和不確定性,可能導致實際業績和業績與前瞻性陳述中討論的結果和業績存在重大差異。這些風險和不確定性包括但不限於以下風險:探索戰略替代方案可能不會導致任何最終交易或提高股東價值,並可能造成分散注意力或不確定性,從而可能對我們的經營業績、業務或投資者的看法產生不利影響;對未來成本和支出的預期;我們的候選產品處於開發初期階段;我們計劃路徑的不確定性以及我們評估和確定這些項目前進道路的能力的不確定性,特別是考慮到我們作爲一家財務、人員和其他運營資源有限的小公司所面臨的限制(包括有限資本的配置以及短期內我們選擇的任何道路的充足資本);Salarius繼續經營的能力;Salarius的資本資源充足;是否有合適的第三方來進行預期的戰略交易;公司是否能夠進行戰略交易,或者是否有任何交易,如果已追求,將以有吸引力的條件成功完成,或完全完成;我們的現金資源是否足以爲公司可預見和不可預見的運營費用和資本需求提供資金;可能影響其現金支出的公司運營計劃的變化;研發、未來臨床數據和分析中固有的不確定性;與裁員相關的風險,包括士氣低落和戰略重組所需的額外員工流失;未來的臨床試驗結果以及此類結果對Salarius的影響;研究和臨床試驗的結果可能無法預測未來的臨床試驗結果;競爭格局和其他行業相關風險;以及Salarius向美國證券交易委員會提交的文件中描述的其他風險,包括其截至2022年12月31日財年的10-K表年度報告,該報告由其向美國證券交易委員會提交的10-Q表季度報告和其他文件進行了修訂或補充。本新聞稿中包含的前瞻性陳述僅代表截至本新聞稿發佈之日,並基於管理層截至該日的假設和估計。Salarius不願有任何意圖或義務更新這些前瞻性陳述以反映其發表之日後存在的事件或情況。

Contact:

聯繫人:

LHA Investor Relations
Kim Sutton Golodetz
kgolodetz@lhai.com
212-838-3777

LHA 投資者關係
金·薩頓·戈洛德茨
kgolodetz@lhai.com
212-838-3777


譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論